Patients carrying anti-melanoma differentiation-associated gene 5 (MDA5) antibodies are likely to develop interstitial lung disease (ILD), particularly rapidly progressive (RP)-ILD, which has a high mortality rate and poor prognosis (Johnson et al., 2016; Abe et al., 2017; Moghadam-Kia et al., 2017). The gene discussed is IFIH1; the disease is interstitial lung disease.